It is important to mention that the rate of response was low in aCML cases compared to MDS/MPN-U, but it is not clear if this is due to a less significant number of aCML cases (four out of a total of 35) or because of other mutations present in aCML cases that might affect the response to ruxolitinib, e.g., SETBP1. This evidence concerns the gene SETBP1 and myeloproliferative disorder.